OncoMatch/Clinical Trials/NCT05691010
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Is NCT05691010 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including Carboplatin and Paclitaxel for endometrial cancer.
Treatment: Carboplatin · Paclitaxel — The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Endometrial Cancer
Biomarker criteria
Excluded: POLE pathogenic mutation
Excluded: Mismatch-repair deficient (MSI-H / dMMR)
Disease stage
Required: Stage FIGO (2009) IIIA, FIGO (2009) IIIC1 (FIGO (2009))
Patients must have FIGO (2009) stage IIIA or IIIC1 disease (as determined by surgical staging).
Performance status
KARNOFSKY OR ECOG 0–1
Karnofsky Performance Status (KPS) ≥ 70 (or ECOG 0 or 1)
Demographics
Prior therapy
Must have received: surgery
Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node surgical assessment (sentinel lymph node mapping and/or sampling). Para-aortic lymph node surgical assessment is optional.
Cannot have received: radiation therapy
No prior radiation therapy for treatment of endometrial cancer.
Cannot have received: chemotherapy
No prior chemotherapy for treatment of endometrial cancer.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1500/mcL; Platelet count ≥ 100,000/mcL
Kidney function
Creatinine ≤ 1.5X ULN
Liver function
AST/ALT ≤ 3X upper limit of normal (ULN); Total bilirubin ≤ 1.5X ULN (≤ 3X ULN if Gilbert's disease)
Patients must have adequate organ function, defined by the following laboratory results no more than 14 days prior to first study treatment: * Absolute neutrophil count (ANC) ≥ 1500/mcL * Platelet count ≥ 100,000/mcL * AST/ALT ≤ 3X upper limit of normal (ULN) * Total bilirubin ≤ 1.5X ULN. Patients with known Gilbert's disease and a total bilirubin ≤ 3X ULN may be enrolled. * Creatinine ≤ 1.5X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (All protocol activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) · Montvale, New Jersey
- Memorial Sloan Kettering Commack (All protocol activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All protocol activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05691010 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with MLH1 alterations eligible?
No. MLH1 loss is an exclusion criterion.
Are patients with MSH2 alterations eligible?
No. MSH2 loss is an exclusion criterion.
What disease stage is eligible?
Stage FIGO (2009) IIIA or FIGO (2009) IIIC1 is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages